Time filter

Source Type

Patent
Zeria Pharmaceutical Co. | Date: 2013-10-16

Provided is a method for effectively producing a 4,5-dialkoxy-2-hydroxybenzoic acid from an inexpensive raw material. A method for producing a 2-bromo-4,5-dialkoxybenzoic acid represented by the following formula (2):(wherein each of R^(1) and R^(2) represents a lower alkyl group), the method including causing a 3,4-dialkoxybenzoic acid represented by the following formula (1):(wherein R^(1) and R^(2) have the same meanings as defined above) to react with bromine in concentrated hydrochloric acid.


Patent
Zeria Pharmaceutical Co. | Date: 2014-09-24

To provide a cancer pain therapeutic and/or prophylactic agent which can be administered to a patient for a long period of time from the early stage to the final stage of the cancer pain therapy, instead of conventional non-opioid analgesic agents or opioid analgesic agents. The cancer pain therapeutic and/or prophylactic agent containing, as an active ingredient, a 1,5-benzodiazepine derivative represented by formula (1): (wherein R^(1 )represents a C_(1-6 )alkyl group, R^(2 )represents a phenyl group or a cyclohexyl group, and Y represents a single bond or a C_(1-4 )an alkylene group) or a pharmaceutically acceptable salt thereof.


Patent
Zeria Pharmaceutical Co. | Date: 2015-12-30

To provide an enteric coated tablet containing a large amount of medicinal ingredient and having sufficient impact resistance, without forming a thick enteric coating layer. The enteric coated tablet contains (A) a core tablet containing a medicinal ingredient and having a weight of 1,000 mg or more; (B) a coating layer containing a water-soluble polymer applied onto the surface of the core tablet; and (C) an enteric coating layer dissolving at pH 7 or higher which is applied onto the surface of the coating layer containing a water-soluble polymer, wherein the sum of the polymer amount of the coating layer (B) and the polymer amount of the coating layer (C) is 10 to 18 mg/cm^(2), the polymer amount of the coating layer (B) is 6 to 12 mg/cm^(2), and the polymer amount of the coating layer (C) is 3 to 6 mg/cm^(2).


Patent
Zeria Pharmaceutical Co. and Saitama University | Date: 2016-02-03

To provide a therapeutic agent for gastrointestinal disorder such as diabetic gastroparesis. A postprandial gastrokinetic agent containing (A) ghrelin or a ghrelin agonist and (B) motilin or a motilin agonist as active ingredients, in which both the ingredients (A) and (B) are administered so as to act on the stomach after food intake.


Patent
Zeria Pharmaceutical Co. and Saitama University | Date: 2014-02-10

To provide a therapeutic agent for gastrointestinal disorder such as diabetic gastroparesis. A postprandial gastrokinetic agent containing (A) ghrelin or a ghrelin agonist and (B) motilin or a motilin agonist as active ingredients, in which both the ingredients (A) and (B) are administered so as to act on the stomach after food intake.


Patent
Zeria Pharmaceutical Co. | Date: 2013-10-29

Provided is a method for selectively demethylating a 2-methoxy group. Specifically provided is a production method of a compound represented by formula (7) below through the following reactions.


Patent
Zeria Pharmaceutical Co. | Date: 2014-12-22

A therapeutic agent for impaired gastric accommodation which contains as an active ingredient a compound represented by the general formula (1): (wherein R^(1 )represents a hydrogen atom, a hydroxyl group or a halogen atom; A represents a furyl group, a thienyl group, a thiazolyl group or an oxazolyl group; R^(2 )and R^(3 )each represents an alkyl group with 1 to 5 carbon atoms; and n represents an integer of 2 to 4), or an acid addition salt thereof. Use of a therapeutic agent of the present invention greatly alleviates symptoms caused by said disorders, such as early satiety and bloating, because it improves relaxation of gastric fundus and impaired gastric accommodation.


Patent
Zeria Pharmaceutical Co. | Date: 2014-02-21

To provide an enteric coated tablet containing a large amount of medicinal ingredient and having sufficient impact resistance, without forming a thick enteric coating layer. The enteric coated tablet contains (A) a core tablet containing a medicinal ingredient and having a weight of 1,000 mg or more; (B) a coating layer containing a water-soluble polymer applied onto the surface of the core tablet; and (C) an enteric coating layer dissolving at pH 7 or higher which is applied onto the surface of the coating layer containing a water-soluble polymer, wherein the sum of the polymer amount of the coating layer (B) and the polymer amount of the coating layer (C) is 10 to 18 mg/cm^(2), the polymer amount of the coating layer (B) is 6 to 12 mg/cm^(2), and the polymer amount of the coating layer (C) is 3 to 6 mg/cm^(2).


Patent
Zeria Pharmaceutical Co. | Date: 2013-10-29

Provided is a method for selectively demethylating a 2-methoxy group. Specifically provided is a production method of a compound represented by formula (7) below through the following reactions.


Patent
Zeria Pharmaceutical Co. | Date: 2013-10-29

Provided is a method for selectively demethylating a 2-methoxy group. Specifically provided is a production method of a compound represented by formula (7) below through the following reactions.

Loading Zeria Pharmaceutical Co. collaborators
Loading Zeria Pharmaceutical Co. collaborators